Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Stoke Therapeutics, Inc." found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Stoke Therapeutics, Inc. for you to read. Along with our medical data and news we also list Stoke Therapeutics, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Stoke Therapeutics, Inc. Companies for you to search.
AstraZeneca and Seres Therapeutics have agreed to a three-year research collaboration to study Seres' SER-401 in combination -More-
The FDA has approved Akari Therapeutics' endpoints for its pivotal study to assess Coversin to treat pediatric patients with -More-
JSR announced today that it will establish a US headquarters for its biotechnology and life sciences focused businesses under the name JSR Life Sciences, LLC effective April 1, 2019. The formation of JSR Life Sciences will centralize leadership and resources to support the company’s value proposition of driving innovation to provide a portfolio of integr...
Exiting Gilead biology leader lands CSO post at blood cancer company Amphivena Therapeutics. Sanofi moves its Brazil general manager to...
Company to host conference call today at 8:00 AM Eastern NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) Read more...
Akebia Therapeutics has reported that two pivotal Phase III clinical trials of its vadadustat drug met their primary endpoints in...Read More... The post Akebia Phase III studies of vadadustat meet primary endpoint appeared first on Drug Development Technology.
Deerfield said the alliance is expected to catalyze the development of novel therapeutics and rapidly drive innovations toward clinical validation.
TEL AVIV, Israel, March 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, March 28th at 8:30am Eastern Time to report fiscal year ended December 31, 2018 fin...
- New commercial strategy including optimized salesforce structure, new distribution network and focus on improving net margins expected to accelerate path to profitability – - Company to host conference call today at 8:30am ET - DALLAS and FORT WORTH, Texas, March 14, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufa...
CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that Frank Haluska, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 29th Annual Hea...
Company achieves FY 2018 total net revenues of $130.4 million FY 2018 operating expenses reduced by $27.2 million, or 18.4% VANCOUVER, British Columbia, and CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” o...
CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced an update with respect to its intention to voluntarily delist its ordinary shares, no par value (the “Ordinary Shares”), from the Tel Aviv Stock Exchange Ltd. (the “TASE”). In accordance with applicable Israeli law and the rules of the TASE, the last...
Whittemore Tingley has been appointed chief medical officer of Tenaya Therapeutics. Tingley comes to the South San Francisco, CA, biotech from Cytokinetics (NASDAQ: CYTK), where he was vice president of clinical research, cardiology. Tenaya spun out of the nonprofit Gladstone Institutes in 2016 to develop regenerative medicine treatments for heart failure.
The Senate Finance Committee invited Cigna, CVS, Humana, UnitedHealth's OptumRx and Prime Therapeutics to testify next month.
Tiburio Therapeutics has appointed Nerissa Kreher to the newly created position of chief medical officer. Kreher held that post at her previous company, Avrobio (NASDAQ: AVRO). Her experience also includes positions at Shire, Zafgen (NASDAQ: ZFGN), and Alexion Pharmaceuticals (NASDAQ: ALXN). In January, Tibiurio launched from biotech accelerator Cydan, backed by $31 million in funding. […]
–Company Expands Scientific Advisory Board with Addition of Experts in Cardiovascular Genetics, Gene Therapy and Molecular Biology– Tenaya Therapeutics, a biopharmaceutical company focused on developing potentially curative treatments for heart disease, today announced that it has strengthened its leadership team with the appointment of W...